WO1999010021A1 - Injectable, biocompatible, hydrophilic gel, process for its preparation and application - Google Patents
Injectable, biocompatible, hydrophilic gel, process for its preparation and application Download PDFInfo
- Publication number
- WO1999010021A1 WO1999010021A1 PCT/BG1998/000011 BG9800011W WO9910021A1 WO 1999010021 A1 WO1999010021 A1 WO 1999010021A1 BG 9800011 W BG9800011 W BG 9800011W WO 9910021 A1 WO9910021 A1 WO 9910021A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- patient
- antibiotic
- per cent
- antiseptic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31573—Accuracy improving means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31586—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by rotationally moving or pivoted actuator, e.g. an injection lever or handle
Definitions
- the invention relates to an injectable, biocompatible, hydrophilic gel for replenishment of missing areas of the soft tissue of man or mammals, or for increasing the soft tissue turgor in various cosmetic operations.
- the invention relates also to a process for preparation and application of the gel.
- a disadvantage of the known methods for introduction of the gel in the tissues is that in a certain number of cases there occurs infection followed by suppuration and rejection of the gel.
- Gels obtained according to the known methods are difficult to manipulate due to their great viscosity.
- the application of the known gels which are offered in concentrations up to 3 per cent, leads in the course of time to loss of part of the injected gel mass (approximately 20 per cent).
- additional reshaping of tissues is often necessitated.
- Another disadvantage of the known gels applied in cosmetic corrections of tissues is that they cannot be used for replacement or obtaining of harder body tissues like, for example, retracted muscles of amputation stumps or imitating the shape of an erected penis.
- polyacrylamide gels used are prepared in a consistence allowing their taking (although difficult) in a syringe.
- the said gels are relatively soft and are more suitable for shaping of soft tissues like breasts, lips and other face or belly areas.
- Harder gels obtained through increased polyacrylamide concentration, over 3.1 per cent for example, are even more viscous and their taking in the syringe constitutes a serious problem.
- the task of the invention is to create an injectable, biocompatible hydrophilic gel allowing to eliminate the danger of infection.
- a further task of the invention is to create a gel allowing preservation of the reshaped tissue volume for a practically indefinite period of time. It is also a task of the invention to create a gel, injectable at polyacrylamide concentration over 3 per cent, and at the same time to improve and facilitate the technique of the gel's introduction in the patient's tissues.
- the gel according to the invention is a spatially cross-linked structure of polyacrylamide incorporating an aqueous solution of NaCI and an anaesthetic.
- the authors of the present invention have ascertained that the addition of an antibiotic and/or antiseptic in suitable concentrations between 0.1 and 0.5 per cent (w/v) sharply reduces the rejection of the gel by the patient.
- the authors have ascertained also that the ground gel with particles size between 0.005 and 2 mm allows for the use of a gel with higher polyacrylamide concentration and that such a gel can be applied in replacement of harder tissues in the body - corrections unknown to have been made so far.
- the authors have ascertained an unexpected effect from the application of the gel according to the present invention at polyacrylamide concentrations between 3 and 4 per cent, the said concentrations allowing preservation of the reshaped tissue volume for a practically indefinite period of time.
- Gel particle size is preferably between 0.2 and 0.8 mm.
- the antibiotic used according to the invention may be selected from a large group of broad-spectrum antibiotics and practically depends solely on the patient's tolerability towards the selected antibiotic. Rocephine, Gentamycin, Cephalexin, Amikacin and other antibiotics can be included in the gel composition. 5-Nitrox, Nelidix, Flagyl, etc. can be selected as antiseptics.
- the invention is not to be limited to a specific antibiotic or antiseptic, because any broad-spectrum antibiotic or antiseptic can be used, as far as it is well tolerated by the patient.
- the gel according to the invention is obtained by dissolving the monomeric acrylamide and methylenebisacrylamide in the required quantity of water, so that a total final concentration between 0.5 and 10 per cent is achieved, adding further to the solution sodium chloride up to a concentration of 0.85 per cent, then adding more anaesthetic (0.1 to 2 per cent) and polymerization catalyst (tertiary amine, for example), accomplishing then the final purification of the ingredients stated hereto by means of an adsorbent, followed by polymerization of the monomers, grinding the obtained gel twice under pressure through sieves of 0.1 up to 0.2 mm mesh resulting in particles of 0.2 up to 0.8 mm size, sterilizing and, finally, mixing the hydrogel prior to injecting with a suitable for the patient antibiotic and/or antiseptic in a concentration of 0.1 up to 0.5 per cent (w/v).
- the gel thus obtained is drawn in through a thick cannula connected by a screw (4) to a syringe which is equipped with a screw-piston (1 ).
- the syringe can be made with different cubic capacity - from 0,5 up to 50 ml - depending on the quantity required for the manipulation.
- One end of the syringe body (3) is threaded for screwing on the end-piece (2).
- the end-piece (2) itself is also threaded at both ends - at the one for the syringe body (3) and at the other - for the piston axle (1 ).
- the invention relates also to a process for application of the gel.
- the patient Prior to the manipulation the patient takes per os a broad-spectrum antibiotic, the same antibiotic being also introduced intravenously in order to create an antibiotic barrier in the patient.
- the preparation proposed can be used for filling of residual body cavities resulting from operative resection of organs, for correction of congenital thoracic malformations of the "shoemaker's breasts" type, the Tru syndrome, for mammary gland neoplasty after amputation due to cancer of the mammary glands and in case of aplasia or hypoplasia of the mammary glands, for correction of deformed cicatrices, as well as retracted amputation stumps according to the artificial limb prepared for the patient in the beginning.
- the good tolerability of the gel makes the latter applicable to different zones of the body for augmentation or correction of surgical and aesthetic malformations.
- Another application sphere of the gel according to the invention is its subcutaneous application for increase of the hairs on the head and further operative transplantation of well-haired skin to the zone without hair.
- the present invention enables the replacement of harder consistency tissues by the use of ground gels with higher polyacrylamide concentration.
- An essential improvement of the technique of drawing in and injection of the gel is the use of a syringe with a cubic capacity from 0,5 up to 50 ml, equipped with a special end-piece and a screw-piston.
- the operator is able to reduce the physical effort required for aspiration and pushing of the gel through thin needles. This is especially true for gels of higher viscosity.
- the improvement provides precise dosing of the quantity of gel introduced in the tissues, which after all helps for the more precise work of the operator.
- the drawing represents a syringe comprising a screw-piston (1 ), an end- piece (2), a main body (3) with a working volume of 0,5 up to 50 ml, and an adapter with a screw (4) for the cannula and the needle.
- a screw-piston (1 )
- an end- piece (2)
- a main body (3) with a working volume of 0,5 up to 50 ml
- an adapter with a screw (4) for the cannula and the needle Exemplary embodiments of the invention Example 1. Preparation of low concentration gel
- the monomers acrylamide and methylenebisacrylamide are diluted in quantity of water required to achieve total final concentration of 3 per cent
- the perfectly clear gel obtained is ground by passing the latter at least twice through a metal net with 0.1 up to 0.2 mm mesh under a pressure of 4 atmospheres until particles of 0.2 up to 0.8 mm size are obtained.
- a slightly opalescent mass is obtained due to the appearance of many surfaces between the liquid and the gel phase.
- the gel is then subjected to sterilization using standard thermal processing.
- One hour prior to the correction of the patient's tissues antibiotic Rocephine is injected into the gel with a syringe in small doses (0.1 ml) in different areas up to a final concentration of 0.2 per cent (w/v).
- Example 2 Preparation of a medium polyacrilamide concentration gel Same as example 1 , except that the final concentration of the gel is 4 per cent and the latter is ground under a pressure of 5-6 atmospheres. The result in this case is that the reshaped tissue preserves its form and no reduction of its volume has been observed.
- Example 3 Preparation of high polyacrylamide concentration gel.
- Example 4 Same as example 1 , except that after polymerization of the monomers the final concentration of which is 5 per cent (w/v) in this case, the gel obtained is ground under a pressure of 6 atmospheres. The process is facilitated by the addition of a physiological solution enriched by 0.2 per cent of Lidocaine.
- Example 4 Same as example 1 , except that after polymerization of the monomers the final concentration of which is 5 per cent (w/v) in this case, the gel obtained is ground under a pressure of 6 atmospheres. The process is facilitated by the addition of a physiological solution enriched by 0.2 per cent of Lidocaine. Example 4.
- Example 5 The manipulations are repeated as in example 1 , 2 or 3, except that antibiotic Gentamycin in a concentration of 0.02 per cent (w/v) is used. Example 5.
- Example 8 Application of the gel Prior to the manipulation the patient takes per os a broad-spectrum antibiotic like Ciprobay (0.4 g), and 1.0 g Rocephine is introduced in the patient intravenously in order to create in him an antibiotic barrier. After surgical cleaning of the entire thorax and the two mammary glands, the operative area is surrounded by sterile linen. A local anaesthesia of the skin is made consecutively on the two breasts, in the base of the mammary glands, in three spots at a distance of 120° .
- the gel prepared according to example 1 or 2 is introduced with a syringe through the anaesthetised skin behind the parenchyma of the mammary glands, depending on the volume of the latter.
- the average quantity varies between 150 and 200 ml per breast.
- the identical volume of the two mammary glands is controlled.
- Example 9 Application of the gel. Antibiotic barrier is created and the patient is anaesthetised according to example 8. The gel prepared according to example 3 is introduced through puncture openings into the amputation stump until the clearance between the artificial limb and the retracted amputation stump is filled and the patient feels the artificial limb comfortable again.
- Example 10 Application of the gel.
- Gel prepared according to example 3 is introduced in special places of a two-wall artificial limb until the clearance between the artificial limb and the retracted amputation stump is filled and the patient feels the artificial limb comfortable again.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Abstract
The invention relates to an injectable, biocompatible, hydrophilic gel for replenishment of missing areas of man's and mammals' soft tissue or for increasing the turgor of the said tissue. The gel is based on polyacrylamide and contains further a well-tolerated by the patient antibiotic and/or antiseptic, the said gel particle size being between 0.005 and 2 mm. The invention relates also to a process for preparation and application of the gel.
Description
INJECTABLE, BIOCOMPATIBLE, HYDROPHILIC GEL, PROCESS FOR ITS PREPARATION AND APPLICATION Technical field The invention relates to an injectable, biocompatible, hydrophilic gel for replenishment of missing areas of the soft tissue of man or mammals, or for increasing the soft tissue turgor in various cosmetic operations. The invention relates also to a process for preparation and application of the gel. State of the art
It is known from Enzymology, Dimitar Kolev, Nauka i Izkustvo Publishing House, Sofia 1988, page 316, and from US patent No. 4 743 258 dated 10.05.1988, that the different tissues and systems in the human organism are indifferent to the polyacrylamide gel. The said gel is used for temporary immobilization of enzymes in the form of gel microspheres, so that after their introduction in the blood system of the organism (Enzymology, Dimitar Kolev), the enzymes remain in an active state but are hidden for the protection system receptors of the organism. The substrates and products of the enzymes thus immobilized are more low-molecular and can pass by diffusion through the pores of the polyacrylamide spheres.
It is known also from Application for invention No. 100 240/21.12.1995 published in the Official Bulletin of the Patent Office, issue 3/1997, that the polyacrylamide gel is used for replenishment of cavities resulting from suppurative processes, road accidents, burns or necessitated surgical interventions. The gel is obtained on the basis of polyacrylamide and includes an anesthetic.
A disadvantage of the known methods for introduction of the gel in the tissues is that in a certain number of cases there occurs infection followed by suppuration and rejection of the gel. Gels obtained according to the known methods are difficult to manipulate due to their great viscosity.
What is more, the application of the known gels, which are offered in concentrations up to 3 per cent, leads in the course of time to loss of part of the injected gel mass (approximately 20 per cent). As a result, additional reshaping of tissues is often necessitated. Another disadvantage of the known gels applied in cosmetic corrections of tissues is that they cannot be used for replacement or obtaining of harder body tissues like, for example, retracted muscles of amputation stumps or imitating the shape of an erected penis. This is due to the fact that polyacrylamide gels used are prepared in a consistence allowing their taking (although difficult) in a syringe. The said gels are relatively soft and are more suitable for shaping of soft tissues like breasts, lips and other face or belly areas. Harder gels obtained through increased polyacrylamide concentration, over 3.1 per cent for example, are even more viscous and their taking in the syringe constitutes a serious problem.
The task of the invention is to create an injectable, biocompatible hydrophilic gel allowing to eliminate the danger of infection. A further task of the invention is to create a gel allowing preservation of the reshaped tissue volume for a practically indefinite period of time. It is also a task of the invention to create a gel, injectable at polyacrylamide concentration over 3 per cent, and at the same time to improve and facilitate the technique of the gel's introduction in the patient's tissues. Technical essence of the invention The gel according to the invention is a spatially cross-linked structure of polyacrylamide incorporating an aqueous solution of NaCI and an anaesthetic. The authors of the present invention have ascertained that the addition of an antibiotic and/or antiseptic in suitable concentrations between 0.1 and 0.5 per cent (w/v) sharply reduces the rejection of the gel by the patient. The authors have ascertained also that the ground gel with particles size between 0.005 and 2 mm allows for the use of a gel with
higher polyacrylamide concentration and that such a gel can be applied in replacement of harder tissues in the body - corrections unknown to have been made so far. What is more, the authors have ascertained an unexpected effect from the application of the gel according to the present invention at polyacrylamide concentrations between 3 and 4 per cent, the said concentrations allowing preservation of the reshaped tissue volume for a practically indefinite period of time. Gel particle size is preferably between 0.2 and 0.8 mm. The antibiotic used according to the invention may be selected from a large group of broad-spectrum antibiotics and practically depends solely on the patient's tolerability towards the selected antibiotic. Rocephine, Gentamycin, Cephalexin, Amikacin and other antibiotics can be included in the gel composition. 5-Nitrox, Nelidix, Flagyl, etc. can be selected as antiseptics. The invention is not to be limited to a specific antibiotic or antiseptic, because any broad-spectrum antibiotic or antiseptic can be used, as far as it is well tolerated by the patient.
The gel according to the invention is obtained by dissolving the monomeric acrylamide and methylenebisacrylamide in the required quantity of water, so that a total final concentration between 0.5 and 10 per cent is achieved, adding further to the solution sodium chloride up to a concentration of 0.85 per cent, then adding more anaesthetic (0.1 to 2 per cent) and polymerization catalyst (tertiary amine, for example), accomplishing then the final purification of the ingredients stated hereto by means of an adsorbent, followed by polymerization of the monomers, grinding the obtained gel twice under pressure through sieves of 0.1 up to 0.2 mm mesh resulting in particles of 0.2 up to 0.8 mm size, sterilizing and, finally, mixing the hydrogel prior to injecting with a suitable for the patient antibiotic and/or antiseptic in a concentration of 0.1 up to 0.5 per cent (w/v). The gel thus obtained is drawn in through a thick cannula connected by a screw (4) to a
syringe which is equipped with a screw-piston (1 ). The syringe can be made with different cubic capacity - from 0,5 up to 50 ml - depending on the quantity required for the manipulation. One end of the syringe body (3) is threaded for screwing on the end-piece (2). The end-piece (2) itself is also threaded at both ends - at the one for the syringe body (3) and at the other - for the piston axle (1 ).
The invention relates also to a process for application of the gel. Prior to the manipulation the patient takes per os a broad-spectrum antibiotic, the same antibiotic being also introduced intravenously in order to create an antibiotic barrier in the patient. The preparation proposed can be used for filling of residual body cavities resulting from operative resection of organs, for correction of congenital thoracic malformations of the "shoemaker's breasts" type, the Poland syndrome, for mammary gland neoplasty after amputation due to cancer of the mammary glands and in case of aplasia or hypoplasia of the mammary glands, for correction of deformed cicatrices, as well as retracted amputation stumps according to the artificial limb prepared for the patient in the beginning. The good tolerability of the gel makes the latter applicable to different zones of the body for augmentation or correction of surgical and aesthetic malformations.
Another application sphere of the gel according to the invention is its subcutaneous application for increase of the hairs on the head and further operative transplantation of well-haired skin to the zone without hair. Advantages
According to the invention, with the application of the gel with over 3 per cent concentration of polyacrylamide, forms preserved for a practically indefinite period of time are obtained. The introduction of the antibiotic in the gel leads to a considerable reduction of the danger of infection. During over 100 implantations made so
far, practically no infection of the round-the-gel area and no rejection of the gel was observed in patients with an antibiotic barrier created prior to the manipulation. The equal distribution of the antibiotic in the harder gels became possible after grinding of the said gels. The phase during which the antiseptic or the antibiotic is introduced, that is, after the thermal sterilization of the gel, allows both selection of a preparation suitable for the patient and use of thermally unstable preparations, i.e. the proposed process does not put limitations to the selection of antimicrobial preparations.
The present invention enables the replacement of harder consistency tissues by the use of ground gels with higher polyacrylamide concentration. An essential improvement of the technique of drawing in and injection of the gel is the use of a syringe with a cubic capacity from 0,5 up to 50 ml, equipped with a special end-piece and a screw-piston. Thus the operator is able to reduce the physical effort required for aspiration and pushing of the gel through thin needles. This is especially true for gels of higher viscosity. The improvement provides precise dosing of the quantity of gel introduced in the tissues, which after all helps for the more precise work of the operator.
Explanation of the enclosed drawing
The drawing represents a syringe comprising a screw-piston (1 ), an end- piece (2), a main body (3) with a working volume of 0,5 up to 50 ml, and an adapter with a screw (4) for the cannula and the needle. Exemplary embodiments of the invention Example 1. Preparation of low concentration gel
The monomers acrylamide and methylenebisacrylamide are diluted in quantity of water required to achieve total final concentration of 3 per cent
(w/v). NaCI is added to the solution so that the final concentration of same becomes 0.85 per cent (w/v), then the anaesthetic Lidocaine - up to 0.2 per
cent (w/v) and a minimum quantity of tertiary amine as polymerisation catalyst. pH of the solution is maintained between 6.5 and 8.0. It is not necessary to set precisely the acidity of the solution because of the extremely low buffer capacity of the latter. Activated carbon for final elimination of eventual pyrogenic substances and other undesired admixtures is added and the solution is stirred at ambient temperature for an hour. The solution is filtered, then persulphate as an initiator of polymerization is added. When the polymerization is completed the perfectly clear gel obtained is ground by passing the latter at least twice through a metal net with 0.1 up to 0.2 mm mesh under a pressure of 4 atmospheres until particles of 0.2 up to 0.8 mm size are obtained. A slightly opalescent mass is obtained due to the appearance of many surfaces between the liquid and the gel phase. The gel is then subjected to sterilization using standard thermal processing. One hour prior to the correction of the patient's tissues antibiotic Rocephine is injected into the gel with a syringe in small doses (0.1 ml) in different areas up to a final concentration of 0.2 per cent (w/v). The gel is then tempered at 37 ' C and an hour after the introduction of the antibiotic is waited to enable the equal distribution of the latter in the gel by diffusion. The mass obtained can be quite easily taken by a thick needle put in a syringe according to the drawing enclosed herein, and then injected into the patient with a thin needle for correction of his malformations. Example 2. Preparation of a medium polyacrilamide concentration gel Same as example 1 , except that the final concentration of the gel is 4 per cent and the latter is ground under a pressure of 5-6 atmospheres. The result in this case is that the reshaped tissue preserves its form and no reduction of its volume has been observed. Example 3. Preparation of high polyacrylamide concentration gel.
Same as example 1 , except that after polymerization of the monomers the final concentration of which is 5 per cent (w/v) in this case, the gel obtained is ground under a pressure of 6 atmospheres. The process is facilitated by the addition of a physiological solution enriched by 0.2 per cent of Lidocaine. Example 4.
The manipulations are repeated as in example 1 , 2 or 3, except that antibiotic Gentamycin in a concentration of 0.02 per cent (w/v) is used. Example 5.
The manipulations are repeated as in example 1 , 2 or 3, except that antibiotic Cephalexin in a concentration of 0.5 per cent (w/v) is used. Example 6.
The manipulations are repeated as in example 1 , 2 or 3, except that antibiotic Amikacin in a concentration of 0.5 per cent (w/v) is used. Example 7.
The manipulations are repeated as in example 1 , 2 or 3, except that antiseptic 5-Nitrox in a concentration of 0.01 per cent (w/v) is used. Example 8. Application of the gel Prior to the manipulation the patient takes per os a broad-spectrum antibiotic like Ciprobay (0.4 g), and 1.0 g Rocephine is introduced in the patient intravenously in order to create in him an antibiotic barrier. After surgical cleaning of the entire thorax and the two mammary glands, the operative area is surrounded by sterile linen. A local anaesthesia of the skin is made consecutively on the two breasts, in the base of the mammary glands, in three spots at a distance of 120° . The gel prepared according to example 1 or 2 is introduced with a syringe through the anaesthetised skin behind the parenchyma of the mammary glands, depending on the volume of the latter. The average quantity varies between 150 and 200 ml per
breast. During the injection the identical volume of the two mammary glands is controlled.
Example 9. Application of the gel. Antibiotic barrier is created and the patient is anaesthetised according to example 8. The gel prepared according to example 3 is introduced through puncture openings into the amputation stump until the clearance between the artificial limb and the retracted amputation stump is filled and the patient feels the artificial limb comfortable again. Example 10. Application of the gel.
Gel prepared according to example 3 is introduced in special places of a two-wall artificial limb until the clearance between the artificial limb and the retracted amputation stump is filled and the patient feels the artificial limb comfortable again.
Claims
1. An injectable, biocompatible, hydrophilic gel for replenishment of missing areas of man's and mammals' soft tissue or for increasing the turgor of the said soft tissue the said gel containing polyacrylamide and an anaesthetic, characterized in that the polyacrylamide concentration is between 0.5 and 10 per cent (w/v) and that the gel contains also a well-tolerated by the patient antibiotic and/or antiseptic in concentrations between 0.01 and 0.5 per cent (w/v) and the gel particles are between 0.005 and 2 mm.
2. A gel according to claim 1, characterized in that the gel particles are between 0.2 and 0.8 mm.
3. A gel according to claim 1 , characterized in that the antibiotic well- tolerated by the patient can be selected from the group of antibiotics including Rocephine, Gentamycin, Cephalexin, Amikacin and others.
4. A gel according to claims 1 to 3, characterized in that the antiseptic can be selected from the group of antiseptics including 5-Nitrox, Nelidix, Flagyl, etc.
5. A process for the preparation of a gel according to claims 1 to 4 wherein the monome c solution of the acrylamide and methylenebisacrylamide containing an anaesthetic and a catalyst is depirogenised, filtered, polymerized and sterilized, characterized in that the polymeric product in concentrations from 0.5 up to 10 per cent (w/v) is ground to particle size between 0.005 and 2 mm prior to the sterilization phase and about an hour before injection of the gel into the patient a well-tolerated by the patient antibiotic and/or antiseptic is added to the gel in concentration between 0.01 and 0.5 per cent (w/v).
6. A process for application of the gel according to claims 1 to 5, characterized in that an antibiotic barrier is created in the patient prior to the introduction of the gel, the said patient taking parentherally or p_er os a well-tolerated by him antibiotic or antiseptic.
7. A syringe for aspiration and injection of the gel according to claims 1 through 4, characterized in that the syringe comprises a screw-piston
(1), an end-piece (2), a main body (3) with a working volume of 0,5 up to 50 ml, and an adapter with a screw (4) for the cannula and the needle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU80047/98A AU8004798A (en) | 1997-08-26 | 1998-06-18 | Injectable, biocompatible, hydrophilic gel, process for its preparation and application |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG101856 | 1997-08-26 | ||
BG10185697 | 1997-08-26 | ||
BG102375 | 1998-04-07 | ||
BG102375A BG102375A (en) | 1997-08-26 | 1998-04-07 | Inoculation biocompatible hydrophilic gel, method for its preparation and application |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999010021A1 true WO1999010021A1 (en) | 1999-03-04 |
Family
ID=25663370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BG1998/000011 WO1999010021A1 (en) | 1997-08-26 | 1998-06-18 | Injectable, biocompatible, hydrophilic gel, process for its preparation and application |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU8004798A (en) |
BG (1) | BG102375A (en) |
WO (1) | WO1999010021A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016453A1 (en) * | 2000-08-25 | 2002-02-28 | Contura S.A. | Polyacrylamide hydrogel and its use as an endoprosthesis |
WO2003026711A1 (en) * | 2001-09-28 | 2003-04-03 | Biopharma Development Ltd | Polyfunctional biocompatible hydrogel and method for the production thereof |
WO2005097218A2 (en) * | 2004-04-08 | 2005-10-20 | Q-Med Ab | Particles for soft tissue augmentation |
USRE38913E1 (en) | 1994-08-10 | 2005-12-06 | Contura Sa | Biocompatible hydrogel |
US6972194B1 (en) * | 1999-12-08 | 2005-12-06 | Dmitry Vladimirovich Zybin | Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic and xenogenic cells |
US7186419B2 (en) | 2000-08-25 | 2007-03-06 | Contura Sa | Polyacrylamide hydrogel for arthritis |
US7678146B2 (en) | 2000-08-25 | 2010-03-16 | Contura A/S | Polyacrylamide hydrogel and its use as an endoprosthesis |
RU2680288C1 (en) * | 2018-05-07 | 2019-02-19 | Казбек Урусханович Кудзаев | Lip cheiloplasty method |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1098727A (en) * | 1954-01-28 | 1955-08-18 | Syringe for multiple hypodermic injections | |
DE1035858B (en) * | 1955-01-20 | 1958-08-07 | Dr Fritz Linder | Injection syringe |
FR1364845A (en) * | 1962-06-06 | 1964-06-26 | Device and method for dispensing very small amounts of material out of a container | |
EP0301966A2 (en) * | 1987-07-28 | 1989-02-01 | Seymour F. Trager | Pharmaceutical compositions for treating degenerative joint disease |
EP0499164A1 (en) * | 1991-02-12 | 1992-08-19 | C.R. Bard, Inc. | Injectable compositions to replace lubricating body fluids |
EP0742022A1 (en) * | 1994-08-10 | 1996-11-13 | Maloe Vnedrencheskoe Predpriyatie "Interfall" | Biologically compatible hydrogel |
EP0784987A2 (en) * | 1996-01-16 | 1997-07-23 | Mentor Corporation | Method of making in situ filler material for mammary, penile and testicular prosthesis and tissue expanders |
-
1998
- 1998-04-07 BG BG102375A patent/BG102375A/en unknown
- 1998-06-18 AU AU80047/98A patent/AU8004798A/en not_active Abandoned
- 1998-06-18 WO PCT/BG1998/000011 patent/WO1999010021A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1098727A (en) * | 1954-01-28 | 1955-08-18 | Syringe for multiple hypodermic injections | |
DE1035858B (en) * | 1955-01-20 | 1958-08-07 | Dr Fritz Linder | Injection syringe |
FR1364845A (en) * | 1962-06-06 | 1964-06-26 | Device and method for dispensing very small amounts of material out of a container | |
EP0301966A2 (en) * | 1987-07-28 | 1989-02-01 | Seymour F. Trager | Pharmaceutical compositions for treating degenerative joint disease |
EP0499164A1 (en) * | 1991-02-12 | 1992-08-19 | C.R. Bard, Inc. | Injectable compositions to replace lubricating body fluids |
EP0742022A1 (en) * | 1994-08-10 | 1996-11-13 | Maloe Vnedrencheskoe Predpriyatie "Interfall" | Biologically compatible hydrogel |
EP0784987A2 (en) * | 1996-01-16 | 1997-07-23 | Mentor Corporation | Method of making in situ filler material for mammary, penile and testicular prosthesis and tissue expanders |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE38913E1 (en) | 1994-08-10 | 2005-12-06 | Contura Sa | Biocompatible hydrogel |
US6972194B1 (en) * | 1999-12-08 | 2005-12-06 | Dmitry Vladimirovich Zybin | Use of polyacrylamide gel for forming a connective-tissue capsule in a mammal for cultivating allogenic and xenogenic cells |
BG66025B1 (en) * | 2000-08-25 | 2010-11-30 | Contura S.A. | Polyacrylamide hydrogel and its use as an endoprosthesis |
US7790194B2 (en) | 2000-08-25 | 2010-09-07 | Contura A/S | Polyacrylamide hydrogel as a soft tissue filler endoprosthesis |
US8216561B2 (en) | 2000-08-25 | 2012-07-10 | Contura A/S | Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflex |
US7935361B2 (en) | 2000-08-25 | 2011-05-03 | Contura A/S | Polyacrylamide hydrogel as a soft tissue filler endoprosthesis |
EP1418188A2 (en) * | 2000-08-25 | 2004-05-12 | Contura S.A. | Polyacrylamide hydrogel and its use as an endoprosthesis |
EP2272881A2 (en) | 2000-08-25 | 2011-01-12 | Contura A/S | Polyacrylamide hydrogel for use in the treatment of arthritis |
AU2001281763B2 (en) * | 2000-08-25 | 2006-07-06 | Contura A/S | Polyacrylamide hydrogel and its use as an endoprosthesis |
US7186419B2 (en) | 2000-08-25 | 2007-03-06 | Contura Sa | Polyacrylamide hydrogel for arthritis |
EP1564230A3 (en) * | 2000-08-25 | 2009-12-09 | Contura A/S | Polyacrylamide hydrogel and its use as an endoprosthesis |
US7678146B2 (en) | 2000-08-25 | 2010-03-16 | Contura A/S | Polyacrylamide hydrogel and its use as an endoprosthesis |
US7780958B2 (en) | 2000-08-25 | 2010-08-24 | Contura Sa | Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux |
EP1418188A3 (en) * | 2000-08-25 | 2004-06-09 | Contura S.A. | Polyacrylamide hydrogel and its use as an endoprosthesis |
WO2002016453A1 (en) * | 2000-08-25 | 2002-02-28 | Contura S.A. | Polyacrylamide hydrogel and its use as an endoprosthesis |
WO2003026711A1 (en) * | 2001-09-28 | 2003-04-03 | Biopharma Development Ltd | Polyfunctional biocompatible hydrogel and method for the production thereof |
AU2005231674B2 (en) * | 2004-04-08 | 2010-09-09 | Q-Med Ab | Particles for soft tissue augmentation |
WO2005097218A3 (en) * | 2004-04-08 | 2005-12-01 | Q Med Ab | Particles for soft tissue augmentation |
WO2005097218A2 (en) * | 2004-04-08 | 2005-10-20 | Q-Med Ab | Particles for soft tissue augmentation |
EP1734894B1 (en) | 2004-04-08 | 2016-08-03 | Q-Med AB | Particles for soft tissue augmentation |
US11458226B2 (en) | 2004-04-08 | 2022-10-04 | Galderma Holding SA | Method of soft tissue augmentation |
US11992580B2 (en) | 2004-04-08 | 2024-05-28 | Palette Life Sciences AB | Method of soft tissue augmentation |
RU2680288C1 (en) * | 2018-05-07 | 2019-02-19 | Казбек Урусханович Кудзаев | Lip cheiloplasty method |
Also Published As
Publication number | Publication date |
---|---|
BG102375A (en) | 1999-11-30 |
AU8004798A (en) | 1999-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11992580B2 (en) | Method of soft tissue augmentation | |
RU2683286C2 (en) | Method for crosslift of hyaluronic acid, method for preparation of injection hydrogel, hydrogel and use thereof | |
CN104395348B (en) | The method for preparing the composition based on hyaluronic acid | |
CA2158638C (en) | A composition and a method for tissue augmentation | |
RU2715234C2 (en) | Implants for sculpting, augmenting or correcting facial features such as chin | |
EP2981303B1 (en) | Filler composition for the treatment of lipoatrophy | |
US20160120528A1 (en) | Hydrogel Pressure Sealant System | |
RU2671837C2 (en) | Method for obtaining injectable hydrogel based on hyaluronic acid containing lidocaine added in powder form, and alkaline agent, sterilised with heat | |
ES2214988T3 (en) | POLYACRYLAMIDE HYDROGEL AND ITS USE AS AN ENDOPROTESIS. | |
JP6000976B2 (en) | Hemostatic formulation containing Takara-bi extract | |
WO1999010021A1 (en) | Injectable, biocompatible, hydrophilic gel, process for its preparation and application | |
WO2017001057A1 (en) | Method of preparing a composition based on hyaluronic acid | |
CA3037651A1 (en) | Hyaluronic acid gel with a divalent zinc cation | |
RU2245723C1 (en) | Method and means for treating the cases of pyoinflammatory diseases of soft tissues | |
KR20220105599A (en) | Biocompatible hydrogel comprising hyaluronic acid, polyethylene glycol, and polysiloxane | |
CN113855849A (en) | Dressing composition and preparation method and application thereof | |
RU2228763C1 (en) | Method for treating the cases of purulent wounds | |
EP2222349B1 (en) | Soft tissue filler | |
RU2449781C2 (en) | Antimicrobial and wound healing agent of hydrogel polymeric matrix | |
US10449214B2 (en) | Use of hyaluronic acid | |
WO2019121694A1 (en) | Injectable compositions of cross-linked hyaluronic acid and bupivacaine, and uses thereof | |
RU2409360C1 (en) | Hemostatic and wound healing agent | |
EP3295968A1 (en) | Combination of collagen and carboxymethyl cellulose and use thereof as a dermal filler |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU BA BG BR BY CA CN CU CZ EE GE HU IL IS JP KE KP KR LR LS MX NO NZ PL RO RU SG SI SK TM TR UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
122 | Ep: pct application non-entry in european phase |